赖诺普利市场 - 按剂量、剂量强度、患者年龄层、应用、配销通路- 全球预测

赖诺普利的市场规模预计在 2024 年至 2032 年间将以 4.8% 的复合年增长率增长，这主要是由于心血管疾病患病率的增加。根据世界卫生组织的数据，心血管疾病是世界上最主要的死亡原因，每年夺走约 1,790 万人的生命。由于人口老化、久坐的生活方式和不良的饮食习惯，这些疾病变得更加普遍，对赖诺普利等有效治疗方法的需求将会激增。

新兴经济体对医疗基础设施和医疗服务的日益关注也将影响市场成长。政府和医疗保健组织正在大力投资改善医疗保健服务，并使基本药物更容易获得和负担得起。赖诺普利仿製药的可用性更高，是品牌药物的成本效益替代品，将进一步扩大产品在低收入人群中的覆盖范围。

该行业分为剂量、剂量强度、患者年龄层、应用、配销通路和地区。

根据剂量，液体细分市场的赖诺普利市场将在 2024 年至 2032 年间获得显着的吸引力，因为它在吞嚥药片有困难的患者（如老年人和幼儿）中越来越受欢迎。液体製剂提供了方便且易于调节的剂型，同时提高了患者的依从性并确保准确的剂量。液体赖诺普利提供的易用性和灵活性将促进该细分市场的成长。

由于全球高血压盛行率不断上升，预计从 2024 年到 2032 年，高血压应用领域的赖诺普利市场将显着成长。赖诺普利通常用于透过舒张血管和降低血压来控制高血压。人们对与未控制的高血压相关的健康风险的认识不断提高，加上筛检和诊断方法的改进，正在刺激该细分市场的扩张。

由于经济的快速发展和医疗基础设施的改善，使人们更容易获得医疗和药品，预计亚太地区赖诺普利产业将在 2024 年至 2032 年期间显着成长。政府加强防治非传染性疾病，加上医疗保险覆盖率的扩大，促进了处方药的广泛采用，进一步推动了区域产品需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 高血压和心血管疾病盛行率上升
    • 人口老化加剧
    • 提高认识和筛检计划
    • 药物输送的创新
  • 产业陷阱与挑战
    • 不良反应和安全问题
    • 替代治疗方案
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按剂量，2021 - 2032

• 主要趋势
• 药片
• 液体

第 6 章：市场估计与预测：按剂量强度，2021 - 2032

• 主要趋势
• 10毫克
• 20毫克
• 25毫克

第 7 章：市场估计与预测：按病患年龄组别划分，2021 - 2032 年

• 主要趋势
• 孩子们
• 成年人

第 8 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 高血压
• 心臟衰竭
• 心臟病发作
• 糖尿病肾病变
• 其他应用

第 9 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• AbbVie Inc.
• Amneal Pharmaceutical, Inc.
• AstraZeneca
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Bausch Health Companies, Inc.
• Cipla Limited
• Hikma Pharmaceutical PLC.
• Lupin Limited
• Merck & Co., Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Limited
• Vitaris Inc.
• Zydus Lifesciences Limited

Lisinopril market size is anticipated to grow at 4.8% CAGR between 2024 and 2032 driven primarily by the increasing prevalence of cardiovascular diseases. As per WHO, cardiovascular diseases are the world's leading cause of death, claiming approximately 17.9 million lives annually. As these conditions become more common due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for effective treatments like lisinopril, will soar.

The increasing focus on healthcare infrastructure and access to medical care in emerging economies will also influence market growth. Governments and healthcare organizations are investing heavily in improving healthcare services and making essential medications more accessible and affordable. The higher availability of generic versions of lisinopril, which are cost-effective alternatives to branded drugs, will further expand the product reach among the lower-income population.

The industry is segmented into dosage, dosage strength, patient age group, application, distribution channel, and region.

Based on dosage, the lisinopril market from the liquid segment will gain significant traction between 2024 and 2032 due to its increasing popularity among patients who have difficulty swallowing pills, such as the elderly and young children. Liquid formulations offer a convenient and easily adjustable dosage form while enhancing patient compliance and ensuring accurate dosing. The ease of administration and flexibility provided by liquid lisinopril will add to the segment growth.

The lisinopril market from the hypertension application segment is anticipated to witness significant growth from 2024 to 2032 owing to the growing prevalence of hypertension worldwide. Lisinopril is commonly prescribed to manage hypertension by relaxing blood vessels and reducing blood pressure. The increasing awareness of the health risks associated with unmanaged hypertension, along with improved screening and diagnostic practices, are stimulating the segment expansion.

Asia Pacific lisinopril industry is anticipated to grow at a notable pace over 2024-2032 attributed to the rapid economic development and improving healthcare infrastructure leading to easy access to medical treatments and pharmaceuticals. Increasing government initiatives to combat non-communicable diseases, coupled with expanding health insurance coverage are facilitating greater adoption of prescription medications, further boosting the regional product demand.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of hypertension and cardiovascular diseases
    • 3.2.1.2 Increasing aging population
    • 3.2.1.3 Growing awareness and screening programs
    • 3.2.1.4 Innovations in drug delivery
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
    • 3.2.2.2 Alternative treatment options
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Dosage, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Tablet
• 5.3 Liquid

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 10 Mg
• 6.3 20 Mg
• 6.4 25 Mg

Chapter 7 Market Estimates and Forecast, By Patient Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Children
• 7.3 Adults

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hypertension
• 8.3 Heart failure
• 8.4 Heart attack
• 8.5 Diabetic kidney disease
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Retail pharmacy
• 9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amneal Pharmaceutical, Inc.
• 11.3 AstraZeneca
• 11.4 Apotex Inc.
• 11.5 Aurobindo Pharma Ltd.
• 11.6 Bausch Health Companies, Inc.
• 11.7 Cipla Limited
• 11.8 Hikma Pharmaceutical PLC.
• 11.9 Lupin Limited
• 11.10 Merck & Co., Inc.
• 11.11 Pfizer Inc.
• 11.12 Sun Pharmaceutical Industries Limited
• 11.13 Teva Pharmaceutical Industries Limited
• 11.14 Vitaris Inc.
• 11.15 Zydus Lifesciences Limited